Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (101-110 of 223) with videos related to

Pageof 23
Sort By:
Leukemia & Lymphoma|October 3, 2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinibJacqueline C Barrientos, Jan A Burger, John C Byrd, et al.
Leukemia & Lymphoma|June 15, 2023
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulationLaura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, et al.
Cancer|May 17, 2016
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicityPhilip A Thompson, Francesco Stingo, Michael J Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Sijin Wen, et al.
British Journal of Haematology|April 14, 2016
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemiaShubhchintan Randhawa, Byung S Cho, Dipanjan Ghosh, et al.
Blood|July 2, 2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsElias Jabbour, Daniel Jones, Hagop M Kantarjian, et al.
Cancer|February 8, 2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibPreetesh Jain, Philip A Thompson, Michael Keating, et al.
British Journal of Haematology|October 22, 2016
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observationMariela Sivina, Lillian Werner, Laura Rassenti, et al.
Haematologica|October 16, 2016
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugsRohit Mathur, Lalit Sehgal, Ondrej Havranek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaPreetesh Jain, Michael J Keating, William G Wierda, et al.
Pageof 23

Showing results (101-110 of 223) with videos related to

Sort By:
Pageof 23
Leukemia & Lymphoma|October 3, 2018
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinibJacqueline C Barrientos, Jan A Burger, John C Byrd, et al.
Leukemia & Lymphoma|June 15, 2023
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulationLaura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, et al.
Cancer|May 17, 2016
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicityPhilip A Thompson, Francesco Stingo, Michael J Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Sijin Wen, et al.
British Journal of Haematology|April 14, 2016
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemiaShubhchintan Randhawa, Byung S Cho, Dipanjan Ghosh, et al.
Blood|July 2, 2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsElias Jabbour, Daniel Jones, Hagop M Kantarjian, et al.
Cancer|February 8, 2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibPreetesh Jain, Philip A Thompson, Michael Keating, et al.
British Journal of Haematology|October 22, 2016
Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observationMariela Sivina, Lillian Werner, Laura Rassenti, et al.
Haematologica|October 16, 2016
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugsRohit Mathur, Lalit Sehgal, Ondrej Havranek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaPreetesh Jain, Michael J Keating, William G Wierda, et al.
Pageof 23